Enfusion, Inc. (NYSE:ENFN) Q2 2023 Results Conference Call August 8, 2023 8:30 AM ET
Company Participants
Iggy Njoku - Head, IR
Oleg Movchan - CEO
Brad Herring - CFO
Conference Call Participants
Kevin McVeigh - Credit Suisse
Parker Lane - Stifel
James Faucette - Morgan Stanley
Callie Valenti - Goldman Sachs
Dylan Becker - William Blair
Operator
Good morning, ladies and gentlemen, and thank you for standing by. Welcome to Enfusion Second Quarter 2023 Earnings Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded.
I'd now like to turn the call over to Iggy Njoku, Head of Investor Relations, to begin.
Iggy Njoku
Good morning, and thank you, operator. We welcome you to Enfusion's second quarter 2023 earnings conference call.
Hosting today's call are Oleg Movchan, Enfusion's Chief Executive Officer, and Brad Herring, Enfusion's Chief Financial Officer. Please note our quarterly Shareholder Letter, which includes our quarterly financial results, have all been posted to our IR website.
I'd like to remind you that today's call may contain forward-looking statements. These forward-looking statements are subject to numerous risks and uncertainties, including those set forth in our filings with the SEC and are available in the Investor Relations section on our website.
Actual results may differ materially from any forward-looking statements we make today. These forward-looking statements speak only as of today, and the company does not assume any obligation or intend to update them following today's call, except as required by law.
In addition, today's call may include non-GAAP measures. These measures should be considered as a supplement to and not a substitute for GAAP financial measures. Reconciliations to the nearest GAAP measure can be found in today's quarterly Shareholder Letter, which is available on the company's website.
With that, I'd like to turn the call over to Oleg to begin.
Oleg Movchan
Good morning, and thank you for joining us today to discuss our results in the second quarter of the year. I'm happy to announce another solid quarter balanced between our top and bottom lines.
Given the current macroenvironment and industry dynamics, our business continues to exhibit strength and agility. Enfusion provides an obvious, differentiated alternative to existing legacy technology and operational capabilities, especially valuable in the context of ongoing revenue pressures experienced by investment managers.
The accelerating quarter-on-quarter client additions, healthy bookings trajectory, increasing average contract value and expanding margins are a testament to the resiliency of our business.